2- ((2- piperidin- 1- ylethyl)thio)quinazolin- 4(3H)- one

Subscribe to Selected New Research on 2-((2-piperidin-1-ylethyl)thio)quinazolin-4(3H)-one

3 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Description: structure in first source

Also Known As:

L 2286; L-2286; L2286 compound

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Piperidines: 7

2-((2-piperidin-1-ylethyl)thio)quinazolin-4(3H)-one: 3

2-Ring Heterocyclic Compounds

Quinazolines: 16

2-((2-piperidin-1-ylethyl)thio)quinazolin-4(3H)-one: 3

Experts

1.	Kiss, Gyongyi N: 1 article (09/2008)
2.	Kálai, Tamás: 1 article (09/2008)
3.	Habon, Tamas: 1 article (09/2008)
4.	Sumegi, Balazs: 1 article (09/2008)
5.	Bartha, Eva: 1 article (09/2008)
6.	Halmosi, Robert: 1 article (09/2008)
7.	Kulcsár, Gyozo: 1 article (09/2008)
8.	Toth, Kalman: 1 article (09/2008)
9.	Hideg, Kálmán: 1 article (09/2008)
10.	Kalman, Endre: 1 article (09/2008)

Related Diseases

1.	Myocardial Infarction 10/01/2005 - "A novel PARP inhibitor, L-2286 [2-[(2-piperidin-1-yletil)thio]quinazolin-4(3H)-one] was administered during ischemia-reperfusion in Langendorff perfused rat hearts and in isoproterenol-induced myocardial infarction" 09/01/2008 - "Both L-2286 and enalapril were tested in a rat model of chronic heart failure after isoproterenol-induced myocardial infarction" Get all the results and reference details, order at left...
2.	Ischemia 10/01/2005 - "L-2286 exerted significant protective effect against ischemia-reperfusion-induced myocardial injury in both experimental models" 10/01/2005 - "More importantly, L-2286 facilitated the ischemia-reperfusion-induced activation of Akt, extracellular signal-regulated kinase, and p38-MAPK in both isolated hearts and in vivo cardiac injury" 10/01/2005 - "A novel PARP inhibitor, L-2286 [2-[(2-piperidin-1-yletil)thio]quinazolin-4(3H)-one] was administered during ischemia-reperfusion in Langendorff perfused rat hearts and in isoproterenol-induced myocardial infarction" Get all the results and reference details, order at left...
3.	Hypertrophy 07/01/2006 - "More importantly, L-2286 repressed the hypertrophy-associated increased phosphorylation of panPKC, PKC alpha/betaII, PKC delta and PKC epsilon, which could be responsible for the activation of the antihypertrophic GSK-3beta" Get all the results and reference details, order at left...
4.	Heart Failure 09/01/2008 - "In conclusion, we demonstrated in an experimental heart failure model that L-2286 decreased the postinfarction myocardial remodeling more effectively than enalapril treatment." 09/01/2008 - "Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure." 09/01/2008 - "Both L-2286 and enalapril were tested in a rat model of chronic heart failure after isoproterenol-induced myocardial infarction" Get all the results and reference details, order at left...
4 Diseases and 3 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Isoproterenol (Isoprenaline)
2.	Protein Kinase C-epsilon
3.	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
4.	Phosphotransferases (Kinase)
5.	Enalapril
6.	glycogen synthase kinase 3 beta
6 Drugs and Important Bio-Agents and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>